Stigmatizing attitudes toward persons with psoriasis among laypersons and medical students - 16/05/19
Abstract |
Background |
Perceived stigma among patients with psoriasis contributes to poor quality of life.
Objective |
To determine the prevalence and predictors of stigmatizing attitudes toward persons with psoriasis among laypersons and medical trainees.
Methods |
Laypersons were recruited from Amazon.com's Mechanical Turk (MTurk) (n = 198). Additionally, 187 medical students were recruited via e-mail. Participants completed an online survey in which they viewed images of persons with visible psoriasis. Participants reported their desire to socially avoid the persons in the images, their emotional responses to the persons in the images, and their endorsement of psoriasis-related stereotypes and myths.
Results |
MTurk participants endorsed social avoidance items such as not wanting to shake hands with (39.4%) or have the persons in the images in their home (32.3%). Participants stereotyped persons with psoriasis as contagious (27.3%) and endorsed the myth that psoriasis is not a serious disease (26.8%). Linear regression analyses showed that having heard of or knowing someone with psoriasis predicted fewer stigmatizing attitudes (P < .05). The medical students reported less stigmatizing attitudes than the MTurk participants (P < .01).
Limitations |
Self-report, single-institution study.
Conclusion |
Stigmatizing views of persons with psoriasis are prevalent among people in the United States. Educational campaigns for the public and medical trainees may reduce stigma toward persons with psoriasis.
Le texte complet de cet article est disponible en PDF.Key words : attitudes, laypersons, medical education, psoriasis, stigma
Abbreviations used : ANCOVA, CI, MTurk, OR, QOL
Plan
Funding sources: Supported by a grant from the Edwin and Fannie Gray Hall Center for Human Appearance at the Perelman School of Medicine at the University of Pennsylvania. Dr Pearl is supported in part by a mentored patient-oriented research career development award from the National Heart, Lung and Blood Institute/National Institutes of Health (grant K23HL140176). Dr Takeshita is supported in part by a mentored patient-oriented research career development award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases/National Institutes of Health (grant 5K23AR068433). |
|
Disclosure: Dr Gelfand served as a consultant for Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen Biologics, Novartis Corp, Regeneron, UCB (Data Safety and Monitoring Board), and Sanofi and Pfizer Inc, receiving honoraria; in addition, he receives research grants (to the Trustees of the University of Pennsylvania) from Abbvie, Janssen, Novartis Corp, Sanofi, Celgene, Ortho Dermatologics, and Pfizer Inc, and he has received payment for CME work related to psoriasis that was supported indirectly by Eli Lilly and Company and Ortho Dermatologics. In addition, Dr Gelfand is a copatent holder of resiquimod for treatment of cutaneous T-cell lymphoma, and he is a deputy editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology. Dr Takeshita receives a research grant from Pfizer Inc (to the Trustees of the University of Pennsylvania) and has received payment for CME work related to psoriasis that was supported indirectly by Eli Lilly and Company and Novartis. Dr Pearl and Dr Wan have no conflicts of interest to disclose. |
|
A preliminary analysis of the current data was presented at the 2018 Meeting International Investigative Dermatology, Orlando, FL, May 16-19, 2018. |
Vol 80 - N° 6
P. 1556-1563 - juin 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?